Results with Lifescozul™
Introduction to the case
When Mr. Luis arrived at LifEscozul Group his diagnosis was Stage IV Lung Cancer with multiple metastases.
Before starting LifEscozul (the most effective formulation made with blue scorpion venom) he had pain in his left clavicle and difficulty sleeping.
Mr. Luis started treatment with LifEscozul (escozul, blue scorpion venom, escoazul) in September 2014, and subsequently started chemotherapy.
Let's see his progress below.
-
Clinical Data
LLuis Diosa, 61 years old at the beginning of treatment with LifEscozul.
-
Symptomatology
Left clavicle pain and difficulty sleeping.
-
Protocol Start
September 2014.
-
Specialist assigned to Grupo LifEscozul™
Dr. Aaron Sarmiento
-
Diagnostics
Stage IV lung cancer, with prevascular, paratracheal, subcarinal, hilar, right and left supraclavicular lymph node metastases, infiltration of the adrenal glands.
Background
<In June 2014, thanks to a screening, Mr. Luis was found to have a mass in his lung. When a biopsy was performed, it showed adenocarcinoma involvement. Subsequently, a PET-CT scan showed mediastinal adenopathies of tumor aspect, prevascular.
His doctors prescribed 4 cycles of chemotherapy with pemetrexed and carboplatin (the combination of these drugs produces better responses to lung cancer). When a CAT scan was performed, the disease was stable and Mr. Luis kept on medical controls.
When he was in the third cycle of chemotherapy, he visited the doctor because of abdominal pain, general malaise and weight loss.
Looking for other treatment options to help him continue fighting his disease, Mr. Luis met with LifEscozul Group and sent us all the documents regarding his case to be evaluated by our Medical Team.
The patient's condition before starting our treatment was as follows:
- Pain in left clavicle.
- Difficulty sleeping.
Mr. Luis started treatment with LifEscozul (the most effective formulation made with blue scorpion venom) in September 2014.
Evolution with LifEscozul™ and actual results
MARCH TO JULY 2015
By March 2015 Mr. Luis was on his fourth cycle of chemotherapy. A CT scan revealed mediastinal adenomegaly (less than 10 millimeters) and the pulmonary nodules were unchanged.
In May 2015 a PET-CT showed bolateral mediastinal hypermetabolic mediastinal adenopathy and cervical level III adenopathy without significant changes, meaning that his disease remained stable.
By July 2015 the disease remained stable and Mr. Luis was prescribed 2 more cycles of chemotherapy and continued with LifEscozul treatment (escozul, blue scorpion venom, escoazul).
MAY 2016
In May 2016, one year and 8 months after starting LifEscozul (the most effective formulation made with blue scorpion venom), Mr. Luis underwent full body scans to find out the status of the disease. Although pathologically sized thoracic adenomegaly persisted, there was no tumor activity and the disease was considered stable.
Mr. Luis continued with maintenance treatment with LifEscozul and kept having follow-up examinations every 6 months.
JANUARY TO AUGUST 2017
In January 2017 Mr. Luis underwent a CT scan, which indicated the presence of multiple nodules in the lung parenchyma indicating that at this time the disease has had a new progression.
Cancer is a disease that has the ability to evolve due to the great genetic diversity of its cells, so there may be periods of increased activity and aggressiveness of the disease that lead to growth and appearance of new tumor lesions.
When this happens, we always proceed to a considerable increase in the dose of LifEscozul (the most effective formulation made with the blue scorpion venom), seeking to control the disease again and restore the patient's quality of life.
In August 2017, a CT scan was performed again, again showing disease progression:
- Evidence of multiple metastatic pulmonary nodules with metabolic increase in progression with respect to the previous study, the dominant one in the right lower lobe.
- Metastatic hypermetabolic adenopathies in the base of the neck bilaterally as well as in the median and pulmonary hilar in progression compared to the previous study.
Given these findings our Medical Team proceeded to increase again the dose of LifEscozul (escozul, blue scorpion venom, escoazul).
JUNE 2018.
The following June 2018 CT scan indicated the following:
- Non-calcified multiple parenchymal parenchymal nodules in both hemithoraxes, unchanged when compared to the two 2017 studies.
- Millimetric calcified nodules, residual at the right lower lobe level.
- Comparison of the current study with previous studies shows no significant variation, findings in relation to stable disease.
MAY 2019
CT scan performed in May 2019 indicated that there were still nodular images in lung parenchyma, some of these have increased in size with respect to previous study indicating a partial response.
APRIL TO SEPTEMBER 2020
In April 2020 Luis' son sends us the following:
"Susana, according to the Oncologist my father's condition is stable, he continues to receive chemotherapy every 21 days. His mood is very good, he has not lost weight, on the contrary he eats very well. He does not present choking or respiratory difficulty and the laboratory tests are within the adequate range".
In June 2020 the CT scan indicated that when comparing all the lesions with previous studies there were no changes in morphology or size, especially those of the right lower lobe.
The study sent in September 2020 indicates that there are no new lesions or alterations and that the elements described were present in the previous study performed and have not been modified in the current study, indicating stability of the disease.
These results demonstrate that the progressive increase of doses of LifEscozul (escozul, blue scorpion venom, escoazul) in conjunction with conventional therapies are effective in preventing the progression of the disease, and this can only be achieved through constant communication between the patient and our Medical Team.
After 6 years of fighting such an aggressive disease, Mr. Luis is stable and has a good quality of life.
We will continue working together so that he has the best possible chances of survival with the best possible quality of life.
Resumen
Mr. Luis was diagnosed in June 2014 with stage IV lung cancer and had metastases in multiple locations.
In September 2014 he started treatment with LifEscozul (the most effective formulation made with blue scorpion venom), and throughout this time we have been able to keep the disease stable thanks to the progressive increase of doses and the combination with traditional medicine.
Although there have been times when the disease has behaved more aggressively, we have been able to control its progression and restore Mr. Luis' quality of life by working together with our team of specialists.
This result is thanks to the communication that Mr. Luis and his family have maintained with our Medical Team, which has allowed us to know first-hand his response to the treatment.
The patient continues to consume LifEscozul (escozul, blue scorpion venom, escoazul) and is leading a normal life with his family, without the disease affecting his activities and physical and mental well-being.
Another important fact to highlight is that the chemotherapy sessions did not generate any side effects for Mr. Luis:
- He eats very well.
- He sleeps normally.
- He has not lost weight.
- His blood tests are normal, which means that the chemotherapy has not affected his immune system.
Treatment with LifEscozul (the most effective formulation made with blue scorpion venom) is a natural product that has the ability to eliminate tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a controller of the disease and the work approach is carried out seeking that the patient can live with his disease with the least possible affectation to his daily routine.
We are the LifEscozul Group and the Results Define Us.
Next case
José Daniel Ibarra
Evolution of the patient Jose Daniel Ibarra. Who entered the LifEscozul Protocol in 2017. He had previously suffered from colorectal cancer with liver metastases, and had been treated with chemotherapy, radiotherapy and surgery. View more
